{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:09:18Z","timestamp":1761919758398},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.path.2013.08.008","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T00:30:57Z","timestamp":1380673857000},"page":"767-794","source":"Crossref","is-referenced-by-count":4,"title":["The Differential Diagnosis of Eosinophilia in Neoplastic Hematopathology"],"prefix":"10.1016","volume":"6","author":[{"given":"Ryan C.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.path.2013.08.008_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/wsbm.86","article-title":"Hematopoietic stem cell: self-renewal versus differentiation","volume":"2","author":"Seita","year":"2010","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"10.1016\/j.path.2013.08.008_bib2","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM199805283382206","article-title":"Eosinophilia","volume":"338","author":"Rothenberg","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.path.2013.08.008_bib3","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood.V79.12.3101.bloodjournal79123101","article-title":"Interleukin-5, eosinophils, and disease","volume":"79","author":"Sanderson","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2169\/internalmedicine.36.179","article-title":"Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis","volume":"36","author":"Horie","year":"1997","journal-title":"Intern Med"},{"key":"10.1016\/j.path.2013.08.008_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2141.2003.04195.x","article-title":"The eosinophilias, including the idiopathic hypereosinophilic syndrome","volume":"121","author":"Brito-Babapulle","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/ajh.23293","article-title":"World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Gotlib","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.path.2013.08.008_bib7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2141.1980.tb07174.x","article-title":"The association of eosinophilia with lymphoblastic leukaemia or lymphoma: a study of seven patients","volume":"45","author":"Catovsky","year":"1980","journal-title":"Br J Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01697986","article-title":"Hypereosinophilic syndrome in Hodgkin\u2019s disease with increased granulocyte-macrophage colony-stimulating factor","volume":"71","author":"Endo","year":"1995","journal-title":"Ann Hematol"},{"key":"10.1016\/j.path.2013.08.008_bib9","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/1097-0142(19920215)69:4<966::AID-CNCR2820690422>3.0.CO;2-H","article-title":"Frequency of eosinophilia in adult T-cell leukemia\/lymphoma","volume":"69","author":"Murata","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.path.2013.08.008_bib10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cancergencyto.2004.01.013","article-title":"Prevalence, breakpoint distribution, and clinical correlates of t(5;12)","volume":"153","author":"Greipp","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.path.2013.08.008_bib11","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1182\/blood-2009-07-143552","article-title":"How I treat hypereosinophilic syndromes","volume":"114","author":"Klion","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib12","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib13","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"68","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1","author":"Bain","year":"2008"},{"key":"10.1016\/j.path.2013.08.008_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06221.x","article-title":"Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy","volume":"134","author":"Ohnishi","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1532\/IJH97.05048","article-title":"Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy","volume":"83","author":"Tanaka","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1016\/j.path.2013.08.008_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/gcc.20014","article-title":"Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia","volume":"40","author":"Safley","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.path.2013.08.008_bib17","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib18","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A\u00a0tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.path.2013.08.008_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib20","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.path.2013.08.008_bib21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":"Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias","volume":"18","author":"Vandenberghe","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2013.08.008_bib22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2005.05863.x","article-title":"Multilineage involvement of the fusion gene in patients with FIP1L1\/PDGFRA-positive hypereosinophilic syndrome","volume":"132","author":"Robyn","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib23","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib24","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.path.2013.08.008_bib25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.leu.2404154","article-title":"Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia","volume":"20","author":"Score","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2013.08.008_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1532\/IJH97.05180","article-title":"Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate","volume":"83","author":"Tashiro","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1016\/j.path.2013.08.008_bib27","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/sj.leu.2404728","article-title":"A\u00a0novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease","volume":"21","author":"Curtis","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2013.08.008_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.10980","article-title":"Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene","volume":"92","author":"Walz","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.path.2013.08.008_bib29","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1038\/sj.onc.1206543","article-title":"Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571\/Glivec","volume":"22","author":"Trempat","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.path.2013.08.008_bib30","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/hmg\/11.12.1391","article-title":"The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA","volume":"11","author":"Baxter","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.path.2013.08.008_bib31","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2013.08.008_bib32","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","article-title":"KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities","volume":"120","author":"Maric","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.path.2013.08.008_bib33","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(02)00046-2","article-title":"Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate","volume":"26","author":"Ault","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.path.2013.08.008_bib34","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.path.2013.08.008_bib35","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1073\/pnas.0932698100","article-title":"Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome","volume":"100","author":"Griffin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.path.2013.08.008_bib36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/onc.2010.476","article-title":"The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in\u00a0vitro","volume":"30","author":"Von Bubnoff","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.path.2013.08.008_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib38","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1182\/blood-2006-01-0285","article-title":"The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)","volume":"107","author":"Von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib39","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.1987.tb02291.x","article-title":"Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association","volume":"67","author":"Keene","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-4608(88)90123-9","article-title":"KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12","volume":"35","author":"Srivastava","year":"1988","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.path.2013.08.008_bib42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0165-4608(91)90142-H","article-title":"Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12). A new association","volume":"51","author":"Berkowicz","year":"1991","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.path.2013.08.008_bib43","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2141.1992.tb06450.x","article-title":"Myelodysplastic syndrome associated with increased bone marrow fibrosis and translocation (5;12)(q33;p12.3)","volume":"82","author":"Lerza","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0165-4608(93)90051-M","article-title":"t(5;12)(q31;p12): a clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia","volume":"65","author":"Wessels","year":"1993","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.path.2013.08.008_bib45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","article-title":"Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta","volume":"107","author":"Steer","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.path.2013.08.008_bib47","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.iac.2007.06.001","article-title":"Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome","volume":"27","author":"Bain","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.path.2013.08.008_bib48","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.leu.2404397","article-title":"Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy","volume":"21","author":"Tokita","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2013.08.008_bib49","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.seminhematol.2012.01.008","article-title":"Eosinophilic myeloid disorders","volume":"49","author":"Noel","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.path.2013.08.008_bib50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2007.03.015","article-title":"Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance","volume":"120","author":"B\u00f6hm","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.path.2013.08.008_bib52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0609.1977.tb02338.x","article-title":"Unique eosinophil granules in a case of T-cell lymphoma","volume":"19","author":"Manthorpe","year":"1977","journal-title":"Scand J Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib53","first-page":"1628","article-title":"A\u00a0new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review","volume":"9","author":"Macdonald","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2013.08.008_bib54","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: a review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.path.2013.08.008_bib55","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.leukres.2007.11.012","article-title":"Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature","volume":"32","author":"Mozziconacci","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.path.2013.08.008_bib56","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/sj.thj.6200561","article-title":"Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases","volume":"5","author":"Vizmanos","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.path.2013.08.008_bib57","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood.V98.13.3778","article-title":"The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: ransforming activity and specific inhibition of FGFR1 fusion proteins","volume":"98","author":"Demiroglu","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib58","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/leu.2009.79","article-title":"LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome","volume":"23","author":"Soler","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2013.08.008_bib59","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/gcc.1195","article-title":"Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL","volume":"32","author":"Fioretos","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.path.2013.08.008_bib60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.leukres.2010.12.014","article-title":"8p11 myeloproliferative syndrome with BCR-FGFR1 rearrangement presenting with T-lymphoblastic lymphoma and bone marrow stromal cell proliferation: a case report and review of the literature","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.path.2013.08.008_bib61","doi-asserted-by":"crossref","first-page":"8129","DOI":"10.1128\/MCB.21.23.8129-8142.2001","article-title":"8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase\/Akt\/mTOR pathways","volume":"21","author":"Guasch","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.path.2013.08.008_bib62","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V93.4.1381","article-title":"The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1","volume":"93","author":"Popovici","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib63","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"176","article-title":"T\u00a0lymphoblastic leukemia\/lymphoma","author":"Borowitz","year":"2008"},{"key":"10.1016\/j.path.2013.08.008_bib64","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1073\/pnas.0404438101","article-title":"PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.path.2013.08.008_bib65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/sj.leu.2401029","article-title":"Cytogenetic response induced by interferon alpha\u00a0in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocation t(8;13)(p11;q12)","volume":"12","author":"Martinez-Climent","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2013.08.008_bib66","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/leu.2012.188","article-title":"Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities","volume":"27","author":"Ren","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2013.08.008_bib67","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"51","article-title":"Chronic eosinophilic leukemia, not otherwise specified","author":"Bain","year":"2008"},{"key":"10.1016\/j.path.2013.08.008_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.path.2013.08.008_bib69","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood.V58.5.1012.1012","article-title":"A\u00a0clinicopathologic correlation of the idiopathic hypereosinophilic syndrome: I: hematologic manifestations","volume":"58","author":"Flaum","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib70","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood.V58.5.1021.1021","article-title":"A\u00a0clinicopathologic correlation of the idiopathic hypereosinophilic syndrome: II: clinical manifestations","volume":"58","author":"Schooley","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib71","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2141.1989.tb04335.x","article-title":"Ring eosinophils in human haematological malignancies","volume":"72","author":"Hern\u00e1ndez","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib72","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.1989.tb00309.x","article-title":"The significance of ring eosinophils in humans","volume":"73","author":"Bain","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib73","first-page":"2","article-title":"Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome","volume":"95","author":"Bain","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib74","first-page":"27","article-title":"A\u00a0morphometric study of normodense and hypodense human eosinophils that are derived in\u00a0vivo and in\u00a0vitro","volume":"137","author":"Caulfield","year":"1980","journal-title":"Am J Pathol"},{"key":"10.1016\/j.path.2013.08.008_bib75","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib76","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood.V93.5.1651","article-title":"Clonality of isolated eosinophils in the hypereosinophilic syndrome","volume":"93","author":"Chang","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib77","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/jcp.28.12.956","article-title":"Agar culture and chromosome analysis of eosinophilic leukaemia","volume":"28","author":"Goldman","year":"1975","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.path.2013.08.008_bib78","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0165-4608(98)00055-7","article-title":"Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): confirmation of eosinophil clonal involvement by fluorescence in situ hybridization","volume":"107","author":"Forrest","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.path.2013.08.008_bib79","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2141.1986.tb04089.x","article-title":"Chromosome and cell culture studies in eosinophilic leukaemia","volume":"62","author":"Parreira","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1016\/j.path.2013.08.008_bib80","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"110","article-title":"Acute myeloid leukemia with recurrent cytogenetic abnormalities","author":"Arber","year":"2008"},{"key":"10.1016\/j.path.2013.08.008_bib81","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.7326\/0003-4819-68-6-1220","article-title":"The hypereosinophilic syndromes","volume":"68","author":"Hardy","year":"1968","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.path.2013.08.008_bib82","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.coi.2005.09.008","article-title":"The hypereosinophilic syndromes: still more heterogeneity","volume":"17","author":"Gleich","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.path.2013.08.008_bib83","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-97-1-78","article-title":"NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations","volume":"97","author":"Fauci","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.path.2013.08.008_bib84","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1398-9995.2004.00465.x","article-title":"Recent advances in pathogenesis and management of hypereosinophilic syndromes","volume":"59","author":"Roufosse","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.path.2013.08.008_bib85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/ehm.11.81","article-title":"Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field","volume":"5","author":"Valent","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.path.2013.08.008_bib86","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/0003-4819-102-1-109","article-title":"Neurologic dysfunction in the idiopathic hypereosinophilic syndrome","volume":"102","author":"Moore","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.path.2013.08.008_bib87","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.iac.2007.07.005","article-title":"Pulmonary eosinophilic syndromes","volume":"27","author":"Wechsler","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.path.2013.08.008_bib88","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1398-9995.2005.00812.x","article-title":"Eosinophilic pneumonias","volume":"60","author":"Cottin","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.path.2013.08.008_bib89","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1053\/j.seminhematol.2012.01.002","article-title":"Therapeutic approaches to patients with hypereosinophilic syndromes","volume":"49","author":"Simon","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.path.2013.08.008_bib90","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"32","article-title":"Chronic myelogenous leukemia, BCR-ABL1 positive","author":"Vardiman","year":"2008"},{"key":"10.1016\/j.path.2013.08.008_bib91","first-page":"253","article-title":"Prognostic factors of hypereosinophilic syndrome: study of 40 cases","volume":"140","author":"Lefebvre","year":"1989","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.path.2013.08.008_bib92","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.leukres.2012.12.016","article-title":"Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature","volume":"37","author":"Podjasek","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.path.2013.08.008_bib93","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"54","article-title":"Mastocytosis","author":"Horny","year":"2008"},{"key":"10.1016\/j.path.2013.08.008_bib94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","article-title":"Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms","volume":"114","author":"Valent","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.path.2013.08.008_bib95","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/157339412799462549","article-title":"Mastocytosis","volume":"8","author":"George","year":"2012","journal-title":"Curr Cancer Ther Rev"},{"issue":"4","key":"10.1016\/j.path.2013.08.008_bib96","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.path.2010.09.003","article-title":"Systemic mastocytosis","volume":"3","author":"George","year":"2010","journal-title":"Surg Path Clinics"},{"issue":"10","key":"10.1016\/j.path.2013.08.008_bib97","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","article-title":"CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis in routinely processed bone marrow biopsy specimens","volume":"28","author":"Sotlar","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.path.2013.08.008_bib98","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J\u00a0Pathol"},{"issue":"2","key":"10.1016\/j.path.2013.08.008_bib99","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000048179","article-title":"Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts","volume":"127","author":"Feger","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"8","key":"10.1016\/j.path.2013.08.008_bib100","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.path.2013.08.008_bib101","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.path.2013.08.008_bib102","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ijlh.12057","article-title":"Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review","volume":"35","author":"Savage","year":"2013","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.path.2013.08.008_bib103","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ajh.23296","article-title":"Myeloid and lymphoid neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges","volume":"88","author":"Savage","year":"2013","journal-title":"Am J Hematol"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918113000883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918113000883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T04:43:20Z","timestamp":1596602600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918113000883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1875918113000883"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2013.08.008","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}